Nature Medicine
- 12, 1256 - 1258 (2006)
Published online: 29 October 2006; | doi:10.1038/nm1503
Molecular ablation of ventricular tachycardia after myocardial infarctionTetsuo Sasano1, 2, Amy D McDonald1, Kan Kikuchi1, 2 & J Kevin Donahue11
Heart and Vascular Research Center, MetroHealth Hospital, Case Western Reserve University School of Medicine, Rammelkamp 653, 2500 MetroHealth Drive, Cleveland, Ohio 44109, USA. 2
Present addresses: Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA (T.S.) and Division of Cardiology, Kyushu Kosei-Nenkin Hospital, Kitakyushu City, Fukuoka 807-8555, Japan (K.K.).
Correspondence should be addressed to J Kevin Donahue kdonahue@metrohealth.org Ventricular tachycardia is a common and lethal complication after myocardial infarction. Here we show that focal transfer of a gene encoding a dominant-negative version of the KCNH2 potassium channel (KCNH2-G628S) to the infarct scar border eliminated all ventricular arrhythmias in a porcine model. No proarrhythmia or other negative effects were discernable. Our results demonstrate the potential viability of gene therapy for ablation of ventricular arrhythmias.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
